Vitality CBD in the Media


See how Vitality CBD is shaping the conversation around wellness, cannabinoid science, and hemp regulation through trusted voices, lived experience, and published expertise.



Image

Cannabis & Tech Today
February 6, 2026

Valentine’s Day Gift Guide 2026: Editor’s Picks

The Vitality CBD Salve is featured in Cannabis & Tech Today’s 2026 Valentine’s Day Gift Guide as a premier choice for enhancing intimacy and shared wellness. Vitality CBD’s commitment to quality is highlighted through the product’s USDA-certified organic full-spectrum CBD, which is combined with lavender and peppermint oils to support relaxation and heightened sensation. The publication emphasizes the brand’s authority in the functional wellness space, noting the salve’s quick-absorbing, vegan formulation and rigorous third-party purity testing.

Read on Cannabis & Tech Today

Image

Cannabis & Tech Today
June 25, 2025

Science, Not Politics, Must Guide Hemp’s Regulatory Future

In this Cannabis & Tech Today column, Scott Mazza, co-founder of Vitality CBD, argues that the future of hemp regulation under the Farm Bill 2025 must be guided by scientific evidence rather than political reaction. Drawing on industry experience, Mazza outlines how research increasingly supports CBD’s role in areas such as anxiety, sleep, and pain management, while warning that regulatory uncertainty and state-level bans undermine consumer trust and responsible operators. He calls for nuanced, science-based federal standards, focused on testing, labeling, and access, to protect consumers without reversing the progress made since hemp legalization, as published in Cannabis & Tech Today.

Read on Cannabis & Tech Today

Image

Cannabis & Tech Today
September 18, 2023

Rescheduling Cannabis Will Reduce Stigma, Increase Research, Encourage Innovation

In an article for Cannabis & Tech Today, Scott Mazza argues that reclassifying cannabis from Schedule I to Schedule III would mark a pivotal shift in U.S. drug policy by reducing stigma, expanding access to scientific research, and aligning federal law with current medical evidence and public opinion. He highlights how rescheduling would ease restrictions on clinical trials, accelerate innovation in areas such as pain management and mental health, and improve access to banking and capital for cannabis businesses. Mazza concludes that grounding cannabis policy in data and science could deliver broad societal, economic, and research benefits while creating a more equitable regulatory environment for the industry.

Read on Cannabis & Tech Today